Organogenesis Holdings (ORGO) Common Equity (2015 - 2026)

Organogenesis Holdings' Common Equity history runs 12 years deep, the most recent figure standing at $244.6 million for Q1 2026.

• On a quarterly basis, Common Equity rose 0.68% year-over-year to $244.6 million in Q1 2026; TTM through Mar 2026 was $244.6 million, a 0.68% increase from a year earlier, with the FY2025 full-year figure at $300.1 million, up 14.16% from the prior year.
• Common Equity retreated to $244.6 million in Q1 2026 per ORGO's latest filing, from $300.1 million in the prior quarter.
• Across five years, Common Equity topped out at $300.1 million in Q4 2025 and bottomed at $233.2 million in Q2 2025.
• The 5-year median for Common Equity is $263.5 million (2024), against an average of $262.8 million.
• Across the five-year window, Common Equity jumped 57.84% in 2022 and retreated 12.63% in 2025, its largest moves.
• Year by year, Common Equity stood at $265.7 million in 2022, then advanced by 4.89% to $278.7 million in 2023, then dropped by 5.66% to $262.9 million in 2024, then rose by 14.16% to $300.1 million in 2025, then fell by 18.52% to $244.6 million in 2026.
• Per Business Quant, the three latest ORGO Common Equity figures stand at $244.6 million (Q1 2026), $300.1 million (Q4 2025), and $255.1 million (Q3 2025).